Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1980 Oct;39(5):457–461. doi: 10.1136/ard.39.5.457

Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine.

P Lewis, B L Hazleman, R Hanka, S Roberts
PMCID: PMC1000585  PMID: 7436577

Abstract

Three hundred and eleven patients with classical or definite rheumatoid arthritis were observed over an 11-year period. This group is of particular interest since 214 patients were given cytotoxic therapy, 203 were treated with azathioprine (52 of these also received chlorambucil or cyclophosphamide), and 11 were treated with cyclophosphamide or chlorambucil alone. Forty-six patients died. This is an excess mortality compared with the expected rate for the general population matched with respect to age and sex. The death rate was higher than expected in the age group 45-64 years but lower in those aged 75 years or over. There were more deaths from neoplasia and ischaemic heart disease in the younger age group. One patient died of lymphosarcoma; treatment had been with corticosteroids, gold, and chloroquine. No other tumours of the reticuloendothelial system were recorded, and no patient developed leukaemia.

Full text

PDF
457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson L. G., Talal N. The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol. 1972 Feb;10(2):199–221. [PMC free article] [PubMed] [Google Scholar]
  2. CAMMARATA R. J., RODNAN G. P., JENSEN W. N. Systemic rheumatic disease and malignant lymphoma. Arch Intern Med. 1963 Mar;111:330–337. doi: 10.1001/archinte.1963.03620270056009. [DOI] [PubMed] [Google Scholar]
  3. COBB S., ANDERSON F., BAUER W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953 Oct 1;249(14):553–556. doi: 10.1056/NEJM195310012491402. [DOI] [PubMed] [Google Scholar]
  4. Cobau C. D., Sheon R. P., Kirsner A. B. Immunosuppressive drugs and acute leukemia. Ann Intern Med. 1973 Jul;79(1):131–132. doi: 10.7326/0003-4819-79-1-131_2. [DOI] [PubMed] [Google Scholar]
  5. Currey H. L., Harris J., Mason R. M., Woodland J., Beveridge T., Roberts C. J., Vere D. W., Dixon A. S., Davies J., Owen-Smith B. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. Br Med J. 1974 Sep 28;3(5934):763–766. doi: 10.1136/bmj.3.5934.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dale G. A., Smith R. B. Transitional cell carcinoma of the bladder associated with cyclophosphamide. J Urol. 1974 Nov;112(5):603–604. doi: 10.1016/s0022-5347(17)59806-7. [DOI] [PubMed] [Google Scholar]
  7. Doll R., Kinlen L. Immunosurveillance and cancer: epidemiological evidence. Br Med J. 1970 Nov 14;4(5732):420–422. doi: 10.1136/bmj.4.5732.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. FORNI A. M., KOSS L. G., GELLER W. CYTOLOGICAL STUDY OF THE EFFECT OF CYCLOPHOSPHAMIDE ON THE EPITHELIUM OF THE URINARY BLADDER IN MAN. Cancer. 1964 Oct;17:1348–1355. doi: 10.1002/1097-0142(196410)17:10<1348::aid-cncr2820171017>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  9. Gordon D. A., Stein J. L., Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med. 1973 Apr;54(4):445–452. doi: 10.1016/0002-9343(73)90040-5. [DOI] [PubMed] [Google Scholar]
  10. Hunter T., Urowitz M. B., Gordon D. A., Smythe H. A., Ogryzlo M. A. Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum. 1975 Jan-Feb;18(1):15–20. doi: 10.1002/art.1780180103. [DOI] [PubMed] [Google Scholar]
  11. Isomäki H. A., Mutru O., Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol. 1975;4(4):205–208. doi: 10.3109/03009747509165257. [DOI] [PubMed] [Google Scholar]
  12. Love R. R., Sowa J. M. Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease. Ann Rheum Dis. 1975 Dec;34(6):534–535. doi: 10.1136/ard.34.6.534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mason M., Currey H. L., Barnes C. G., Dunne J. F., Hazleman B. L., Strickland I. D. Azathioprine in rheumatoid arthritis. Br Med J. 1969 Feb 15;1(5641):420–422. doi: 10.1136/bmj.1.5641.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McCracken J. D. Letter: Additional risk from immunosuppressive therapy for rheumatoid arthritis. Ann Intern Med. 1973 Oct;79(4):611–612. doi: 10.7326/0003-4819-79-4-611. [DOI] [PubMed] [Google Scholar]
  15. Miller D. G. The association of immune disease and malignant lymphoma. Ann Intern Med. 1967 Mar;66(3):507–521. doi: 10.7326/0003-4819-66-3-507. [DOI] [PubMed] [Google Scholar]
  16. Moesmann G. Malignancy and mortality in subacute rheumatoid arthritis in old age. Acta Rheumatol Scand. 1969;15(3):193–199. doi: 10.3109/rhe1.1969.15.issue-1-4.28. [DOI] [PubMed] [Google Scholar]
  17. Mutru O., Koota K., Isomäki H. Causes of death in autopsied RA patients. Scand J Rheumatol. 1976;5(4):239–240. doi: 10.3109/03009747609099912. [DOI] [PubMed] [Google Scholar]
  18. Penn I. The incidence of malignancies in transplant recipients. Transplant Proc. 1975 Jun;7(2):323–326. [PubMed] [Google Scholar]
  19. Schneck S. A., Penn I. De-novo brain tumours in renal-transplant recipients. Lancet. 1971 May 15;1(7707):983–986. doi: 10.1016/s0140-6736(71)91384-5. [DOI] [PubMed] [Google Scholar]
  20. Schwartz R. S. Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet. 1972 Jun 10;1(7763):1266–1269. doi: 10.1016/s0140-6736(72)90985-3. [DOI] [PubMed] [Google Scholar]
  21. Seidenfeld A. M., Smythe H. A., Ogryzlo M. A., Urowitz M. B., Dotten D. A. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol. 1976 Sep;3(3):295–304. [PubMed] [Google Scholar]
  22. TALAL N., BUNIM J. J. THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME. Am J Med. 1964 Apr;36:529–540. doi: 10.1016/0002-9343(64)90101-9. [DOI] [PubMed] [Google Scholar]
  23. Tolchin S. F., Winkelstein A., Rodnan G. P., Pan S. F., Nankin H. R. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1974 Jul-Aug;17(4):375–382. doi: 10.1002/art.1780170406. [DOI] [PubMed] [Google Scholar]
  24. Uddin J., Kraus A. S., Kelly H. G. Survivorship and death in rheumatoid arthritis. Arthritis Rheum. 1970 Mar-Apr;13(2):125–130. doi: 10.1002/art.1780130204. [DOI] [PubMed] [Google Scholar]
  25. Urowitz M. B., Gordon D. A., Smythe H. A., Pruzanski W., Ogryzio M. A. Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum. 1973 May-Jun;16(3):411–418. doi: 10.1002/art.1780160319. [DOI] [PubMed] [Google Scholar]
  26. Walder B. K., Robertson M. R., Jeremy D. Skin cancer and immunosuppression. Lancet. 1971 Dec 11;2(7737):1282–1283. doi: 10.1016/s0140-6736(71)90602-7. [DOI] [PubMed] [Google Scholar]
  27. Wall R. L., Clausen K. P. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med. 1975 Aug 7;293(6):271–273. doi: 10.1056/NEJM197508072930604. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES